NNMT inhibitor vs HGH fragment — both reduce fat in preclinical models but through completely different mechanisms. Here's how to think about the difference.
5-Amino-1MQ targets the metabolic machinery inside fat cells — specifically by inhibiting an enzyme (NNMT) that impairs fat oxidation and NAD+ production in obese adipose tissue. AOD-9604 signals fat cells to release stored fat through β3-adrenergic receptor activation — it's a lipolytic trigger derived from HGH. Both reduce fat mass in preclinical models, but via completely different biological layers. They don't compete for the same targets and are sometimes combined in research protocols for this reason.
5-Amino-1MQ blocks NNMT — an enzyme that is overexpressed in obese adipose tissue and that consumes NAD+ precursors and SAM (the cellular methyl donor). By inhibiting NNMT, 5-Amino-1MQ restores cellular NAD+ levels and SAM availability, which improves mitochondrial function in fat cells, increases fat oxidation rate, and normalizes the epigenetic environment that regulates fat cell metabolism. It works from inside the cell, on the metabolic infrastructure.
AOD-9604 is the C-terminal fragment (amino acids 177–191) of human growth hormone. It mimics HGH's fat-mobilizing effects without the growth-promoting or insulin-antagonizing effects of the full molecule. AOD-9604 activates β3-adrenergic receptors on fat cells, triggering hormone-sensitive lipase to break down stored triglycerides into free fatty acids (lipolysis). It also inhibits lipogenesis (new fat formation). It works from outside the cell, on membrane receptors.
5-Amino-1MQ improves the metabolic capacity of fat cells — making them better at burning fat. AOD-9604 tells fat cells to release stored fat via receptor signaling. Both result in fat reduction, but 5-Amino-1MQ changes the cellular environment while AOD-9604 triggers an acute signaling cascade. These are not redundant approaches.
| Factor | 5-Amino-1MQ | AOD-9604 |
|---|---|---|
| Classification | Small molecule (quinolinium) | Peptide (HGH fragment 177–191) |
| Primary target | NNMT enzyme (intracellular) | β3-adrenergic receptor (cell surface) |
| Mechanism type | Metabolic enzyme inhibition | Receptor-mediated lipolytic signaling |
| Route | Oral or SubQ | SubQ primarily |
| Research dose | 50–75mg/day oral | 300–500mcg/day SubQ |
| Metabolic rate effect | Yes — increases resting O₂ consumption | Minimal direct effect |
| Adipogenesis inhibition | Yes (preclinical) | Yes (preclinical) |
| Visceral fat targeting | General adipose | Both subcutaneous and visceral |
| Muscle preservation | Some preclinical evidence | Minimal data |
| HGH-related effects | None | Minimal (no GH receptor binding) |
| Clinical trials | None | Phase 2 completed |
| Human safety data | None | Phase 2 safety data available |
| Research Goal | Lean Toward | Rationale |
|---|---|---|
| Direct lipolysis / fat mobilization | AOD-9604 | β3-AR activation is the cleaner acute lipolytic mechanism |
| Metabolic rate improvement | 5-Amino-1MQ | Resting O₂ consumption data is more direct |
| Oral protocol preferred | 5-Amino-1MQ | Small molecule oral bioavailability advantage |
| Established human safety data | AOD-9604 | Phase 2 data vs zero human trials for 5-Amino-1MQ |
| NAD+ optimization research | 5-Amino-1MQ | NNMT inhibition is the mechanism; AOD has no NAD+ effects |
| Pairing with GLP-1 agonist | 5-Amino-1MQ | Metabolic machinery target doesn't overlap with GLP-1 signaling |
| Broadest coverage | Stack both | Non-overlapping mechanisms — commonly combined in fat loss protocols |
COA-verified vendor pricing with promo codes. Both S1 Research and Tegridy Research carry 5-Amino-1MQ.
View Pricing → Dosage Calculator